InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

InflaRx N.V. (NASDAQ: IFRX) opened Friday in the red. The German-based biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced that it will ...

Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...

The alternative text for this image may have been generated using AI. Figure 4: Evidence for thrombin as a C5 convertase. The alternative text for this image may have been generated using AI. Our ...

The AMD-powered C5a instances offer high performance while consuming 10% less cost compared to its competitors. They come in eight sizes and are generally available starting today. Starting today, ...

In sepsis, activation of the complement system introduces large amounts of C5a into the circulation. The excess of this peptide paralyzes neutrophils and increases susceptibility to infection. In ...

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...